Biotech company avoids bankruptcy with funding round
Danish-based biotech company Azanta pulled off a funding round in support of a novel cancer drug last week. It was cause for celebration, but there is till one regulatory hurdle to pass.
BY LONNI LYNGE
The Danish pastry was piled up high on the table at the headquarters of Danish biotech company Azanta Monday morning, as the company celebrated a successful funding round pulled of last week with a morning feast.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Azanta takes final step before application
For abonnenter
Azanta CEO: We have money to last to 2017
For abonnenter
Azanta raises EUR 7 million
For abonnenter
